Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline Posted on December 3, 2024December 4, 2024 by KBD Admin
Gilead and Tubulis Enter into Exclusive Option and Licence Agreement to Develop ADC Candidate for Select Solid Tumor Target Posted on December 3, 2024December 4, 2024 by KBD Admin
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 Posted on December 2, 2024December 4, 2024 by KBD Admin
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity Posted on November 26, 2024November 27, 2024 by Frazier Web Host
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement Posted on October 31, 2024November 5, 2024 by KBD Admin
MBX Biosciences Announces Pricing of Initial Public Offering Posted on September 13, 2024September 26, 2024 by KBD Admin
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline Posted on July 16, 2024September 26, 2024 by KBD Admin
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer Posted on June 27, 2024September 26, 2024 by KBD Admin
Disc Medicine Announces Underwritten Offering of Common Stock Posted on June 14, 2024September 26, 2024 by KBD Admin
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market Posted on June 14, 2024September 26, 2024 by KBD Admin
